Results
We identified 186 patients who received rituximab between 2011 and 2020 at our Institution, of whom, 94 met the study eligibility criteria. Patients with histologically unproven B-NHL (n=4), non-B-NHL (n=8), indolent B-NHL (n=76) or high-grade B-NHL who only received a single dose of rituximab (n=4), either because of reaction at infusion (n=3) or cardiac arrhythmia (n=1) were excluded from this analysis (Figure 1).